, Volume 49, Issue 3, pp 598–606

Intracellular sodium increase and susceptibility to ischaemia in hearts from type 2 diabetic db/db mice

  • R. Anzawa
  • M. Bernard
  • S. Tamareille
  • D. Baetz
  • S. Confort-Gouny
  • J. P. Gascard
  • P. Cozzone
  • D. Feuvray



An important determinant of sensitivity to ischaemia is altered ion homeostasis, especially disturbances in intracellular Na+\({\left( {Na^{ + }_{i} } \right)}\) handling. As no study has so far investigated this in type 2 diabetes, we examined susceptibility to ischaemia–reperfusion in isolated hearts from diabetic db/db and control db/+ mice and determined whether and to what extent the amount of\(Na^{ + }_{i} \) increase during a transient period of ischaemia could contribute to functional alterations upon reperfusion.


Isovolumic hearts were exposed to 30-min global ischaemia and then reperfused. 23Na nuclear magnetic resonance (NMR) spectroscopy was used to monitor\(Na^{ + }_{i} \) and 31P NMR spectroscopy to monitor intracellular pH (pHi).


A higher duration of ventricular tachycardia and the degeneration of ventricular tachycardia into ventricular fibrillation were observed upon reperfusion in db/db hearts. The recovery of left ventricular developed pressure was reduced. The increase in\( Na^{ + }_{i} \) induced by ischaemia was higher in db/db hearts than in control hearts, and the rate of pHi recovery was increased during reperfusion. The inhibition of Na+/H+ exchange by cariporide significantly reduced \(Na^{ + }_{i} \) gain at the end of ischaemia. This was associated with a lower incidence of ventricular tachycardia in both heart groups, and with an inhibition of the degeneration of ventricular tachycardia into ventricular fibrillation in db/db hearts.


These findings strongly support the hypothesis that increased \(Na^{ + }_{i} \) plays a causative role in the enhanced sensitivity to ischaemia observed in db/db diabetic hearts.


Cardiac ischaemia–reperfusion Db/db mice Intracellular sodium Type 2 diabetes Ventricular arrhythmias 



slowly inactivating component of Na+ current


left ventricular developed pressure


left ventricular end diastolic pressure

\({\text{Na}}^{{\text{ + }}}_{{\,{\text{i}}}} \)

intracellular sodium


Na+/H+ exchange


nuclear magnetic resonance


intracellular pH


thulium(III)-1,4,7,10-tetraazacyclododecane-N,NI,NII,NIII-tetra-(methylene phosphonate)


ventricular fibrillation


ventricular tachycardia


Several studies suggest that type 2 diabetes mellitus has direct adverse effects on the heart, independently of obstructive coronary artery disease [1]. Both clinical [2] and experimental [3] investigations have indeed pointed to a cardiomyopathy in humans producing abnormalities in ventricular function. However, relatively few experimental studies on the possible mechanisms of ventricular dysfunction have been performed in animal models of type 2 diabetes [4, 5, 6]. Diabetic db/db mice provide an animal model of type 2 diabetes [7]. The natural progression of diabetes in db/db mice, with initial insulin resistance followed by an insulin-secretion defect [8], is similar to the pathogenesis of type 2 diabetes in humans [9]. Recent studies using perfused working hearts from diabetic db/db mice have demonstrated altered cardiac metabolism and reduced contractile performance [5, 6]. Reduced cardiac function was also assessed in vivo in 12-week-old diabetic db/db mice [10]. Impaired metabolism, i.e. increased fatty acid oxidation and decreased glucose utilisation, appeared to be an important causative factor in the contractile dysfunction [5, 6]. To date, only a few investigators have reported results from ischaemia–reperfusion studies using db/db hearts [6]. At 6 weeks, db/db hearts showed normal recovery of contractile function following ischaemia, whereas at 12 weeks function was markedly reduced [6].An important determinant of sensitivity to ischaemia is altered ion homeostasis, especially disturbances in intracellular Na+\({\left( {Na^{ + }_{i} } \right)}\) handling [11, 12]. As no study has so far investigated this in type 2 diabetes and altered Na+ handling may indeed have functional as well as pro-arrhythmogenic consequences [13], we examined susceptibility to ischaemia–reperfusion in isolated hearts from 12- to 15-week-old db/db mice and from age-matched control db/+ mice, and determined whether and to what extent the amount of \(Na^{ + }_{i} \) increase, monitored through 23Na nuclear magnetic resonance (NMR) spectroscopy during a transient period of ischaemia, could contribute to functional alterations upon reperfusion. 31P NMR spectroscopy was also used to monitor intracellular pH (pHi), since the accumulation of H+, i.e. a decrease in pHi during severe ischaemia, is a promoting factor for the imbalance of other cations, especially Na+ [14, 15, 16]. In addition, since it is known that Na+/H+ exchange (NHE) contributes to Na+ overload and that inhibitors of NHE exert substantial protection when present throughout ischaemia and reperfusion [16, 17], we compared the effects of NHE inhibition by cariporide in diabetic and control mouse hearts. A preliminary report on this study, in which \(Na^{ + }_{i} \) as non-invasively measured in the beating perfused mouse heart, has already been published [18].

Materials and methods

Experimental animals

Animals were cared for and used in accordance with the European convention for the protection of vertebrate animals used for experimental purposes, and institutional guidelines no. 86/609/CEE November 24, 1986. Male C57BL/KsJ-leprdb/leprdb diabetic (db/db) mice and their non-diabetic control littermates C57BL/KsJ-leprdb/lepr+(db/+) were purchased from Janvier (Le Genest St. Isle, France). All animals used in this study were males between 12 and 15 weeks of age. The animals were housed in groups (five or six) and given free access to food and water.

Heart perfusions

Mice (fed dietary status) were anaesthetised with sodium pentobarbital (100 mg/kg) and heparinised (100 U) i.p. The heart was quickly removed and placed in ice-cold Krebs–Henseleit bicarbonate buffer. After removing extraneous tissues, the aorta was cannulated with an 18-gauge steel cannula (in NMR study groups, with an 18-gauge plastic cannula). The heart underwent a Langendorff perfusion (80 mmHg perfusion pressure) with modified Krebs–Henseleit bicarbonate perfusate, consisting of (mmol/l): NaCl 118, KCl 5.9, MgSO4 1.2, NaHCO3 25, CaCl2 1.75, EDTA 0.5, glucose 11, gassed with 95% O2/5% CO2 (pH 7.4, 37°C) (20-min stabilisation period) and was then immersed in a set volume of warmed perfusate (37°C) so that coronary flow could be estimated by timed collection of coronary effluent. All perfusion solutions were filtered (0.8 μm; Millipore) prior to use. Isovolumic left ventricular developed pressure (LVDP) was monitored using a fluid-filled polyvinylchloride film balloon inserted into the left ventricle via the mitral valve, and was connected to a Statham 23 ID pressure transducer. The initial left ventricular end diastolic pressure (LVEDP) was adjusted to 8–10 mmHg. LVDP was calculated by subtracting LVEDP from systolic pressure. Pressure signals were recorded on a Gould 2,200 recorder (Gould Instruments, Ballainvilliers, France) and IOX data acquisition system (EMKA Technologies, Paris, France). For all experiments, hearts were allowed to contract spontaneously. For 23Na NMR measurements, we used the shift agent thulium(III)-1,4,7,10-tetraazacyclododecane-N,NI,NII,NIII-tetra-(methylene phosphonate) (TmDOTP5−) (Macrocyclics, Dallas, TX, USA), as previously described [11]. TmDOTP5− was dissolved in H2O and subsequently added to the perfusate to reach a concentration of 3.5 mmol/l. Since TmDOTP5− is a sodium salt that binds Ca2+ to a significant extent, both Na+ and Ca2+ were corrected. NaCl was adjusted to keep the total Na+content unchanged, and the total Ca2+ content was increased to 3.42 mmol/l, resulting in a free ionised Ca2+ of 0.85–0.95 mmol/l, measured by using a Ca2+ ion-selective electrode (Orion).

NMR spectroscopy

The 23Na and 31P spectra were recorded on a spectrometer (AM 400 WB; Bruker BioSpin, Ettlingen, Germany) at 105.84 and 161.98 MHz, respectively, using a multinuclear NMR probe. The spectrometer was equipped with a 9.4 T vertical magnet and the perfused heart was inserted into a multinuclear 10-mm diameter glass NMR tube, in which the temperature was maintained at 37°C. Magnetic field homogeneity was optimised using the 1H resonance of H2O. Each Na NMR spectrum (1-min time-resolved) was obtained by accumulation of 280 consecutive free induction decays using 90° pulses and a 205-ms interpulse delay with a 2,500-Hz spectral width and a 1-k data points time domain. 23Na NMR spectra were processed for the quantitative analysis of the intracellular component \({\left( {Na^{ + }_{i} } \right)}\) in two steps. First, removal of the overlapping spectral extracellular component was carried out by the HLSVD method [19]. Second, the\(Na^{ + }_{i} \) peaks were quantified with a time domain fitting routine (AMARES) [20]. The Na+ resonance of a standard solution containing a fixed amount of Na+ and TmDOTP5− in a glass capillary was used for absolute quantification. Eighteen pre-ischaemic spectra were obtained followed by spectra collected over 30 min of ischaemia (30 spectra). Na+ spectra were not collected during reperfusion because we found there to be a negative effect of the presence of Na+ shift reagent on coronary flow rate at reperfusion (effect on coronary flow has been previously noted by others [21]), which appeared to be deleterious at reflow after severe ischaemia in the mouse heart. 31P spectra were obtained from 288 free induction decays following 75° pulses repeated every second using 4-k data points and a 6,000 Hz spectral width (5-min time-resolved spectra). To study changes in pHi during the early phase of reflow following ischaemia with greater time resolution, 1-min time-resolved spectra were acquired. Values for pHi were derived from the chemical shift of the inorganic phosphate resonance as previously described [11]. In some of the experiments we observed heterogeneity of the inorganic phosphate peaks during reperfusion. The averaged inorganic phosphate chemical shifts were therefore used to calculate pHi.

Experimental protocol

The experimental protocol consisted of 15 min of control perfusion followed by 30 min of no-flow ischaemia and 40 min of reperfusion. In all study groups, except when otherwise mentioned, perfusate contained a similar free ionised Ca2+ concentration (0.9 mmol/l), adjusted by using 0.5 mmol/l EDTA when Na+ shift agent was not used. In each group, diabetic or non-diabetic hearts either received or did not receive the NHE inhibitor cariporide (1 μmol/l; a gift from Aventis Pharma) [22]. When present, cariporide was added to the perfusion solution 10 min before inducing ischaemia and was present throughout.

Arrhythmia study

Unipolar ECG was recorded continuously on a Gould 2,200 recorder (Gould Instruments) from perfused hearts, using a reference electrode connected to the steel cannula and a silver electrode flanking the heart. Chart speed was set at 10 mm/s during control perfusion and ischaemia. A few seconds before reperfusion, it was set at 25 or 50 mm/s so as to obtain a permanent high-speed recording [23]. The ECG was retrospectively analysed, in a blind manner, for the incidence, time to onset, and duration of ventricular tachycardia (VT) and ventricular fibrillation (VF) during reperfusion. All analyses were carried out in accordance with the Lambeth Conventions [24]. VT was defined as four or more consecutive premature beats of ventricular origin, and VF was defined as a signal in which individual QRS deflections could no longer be distinguished from one another and for which the rate could not be determined.

Analysis of plasma metabolites

Blood samples (fed dietary status) were taken from the body cavity after excision of the heart. The blood was centrifuged in an Eppendorff centrifuge at 17,000 g and 4°C for 15 min. The resulting plasma sample was stored at −20°C before analysis. Plasma glucose and triglyceride levels were measured with kits from J2L Elitech (Labarthe-Inard, France).

Statistical analysis

Results are presented as means±SEM. The data were analysed using either Student’s t–test for unpaired data or ANOVA followed by the appropriate post–hoc test to locate differences between groups. Binominally distributed variables, such as the incidence of VT or VF, were compared using the χ2 test for a 2×n table, followed by a sequence of 2×2 χ2 tests with Yates’s correction. Significance was set at p<0.05.


Animal characteristics

At 12–15 weeks of age, diabetic db/db mice weighed significantly more than their control non-diabetic db/+littermates (Table 1). This observation is in agreement with previous studies [5, 6]. Heart weight was similar in both groups of mice. As expected [5], db/db mice had significantly elevated plasma levels of glucose and triglyceride, reflecting their diabetic status with hyperglycaemia and hyperlipidaemia.
Table 1

Characteristics of control (db/+) and diabetic (db/db) mice (n=9/group)


Control db/+

Diabetic db/db

Body weight (g)



Heart dry weight (mg)



Plasma glucose (mmol/l)



Plasma triglycerides (mmol/l)



Values are means±SEM. Plasma samples were collected from fed mice

*Significantly different from control

Ventricular function in hearts from db/db mice

We first tested, in pilot experiments, the response of the hearts to standard perfusate buffer Ca2+ concentrations. LVDP measured after 30-min perfusion with nominally 2.0 mmol/l Ca2+(approximately 1.75 mmol/l ionised Ca2+) was in the range of values previously reported for the mouse heart under similar conditions [25, 26], with no difference between control and diabetic hearts (Fig. 1). Decreasing perfusate calcium from 1.75 to 1.25 and then to 0.9 mmol/l ionised Ca2+ decreased LVDP, as previously described [25, 26], again with no significant difference in hearts from diabetic mice compared with hearts from non-diabetic mice (Fig. 1). Nor was there any significant difference in coronary flow rate (2.2±0.2, n=11, and 2.4±0.2 ml/min, n=12, in db/+and db/db hearts, respectively) or heart rate (378±10, n=9, and 352±10 beats/min, n=11, in db/+and db/db hearts, respectively) between hearts from the two groups.
Fig. 1

Mean±SEM values of left ventricular developed pressure (LVDP) after 30 min of control perfusion with perfusate containing either 1.75 or 1.25 mmol/l (n=6 db/db and db/+ hearts for each concentration) or 0.9 mmol/l (n=7 db/db and db/+ hearts) ionised Ca2+. *p<0.05 vs 1.75 mmol/l. Results from db/db hearts, grey bars; results from db/+ hearts, open bars

During ischaemia, LVDP rapidly decreased to zero for all groups whereas LVEDP increased. LVEDP increase (Fig. 2) was not significantly different between groups over the entire period of ischaemia except for a slightly smaller increase in the db/db hearts in the presence of cariporide (only significant at 20 min of ischaemia, p<0.05). There were no significant differences in LVEDP during reperfusion between db/db and db/+ hearts and between hearts in each group receiving or not receiving cariporide. Correct measurements of LVDP upon reperfusion were not possible at some time points over the first 15–20 min, depending on heart groups, due to the development of reperfusion-induced arrhythmias (Fig. 3a, b). Fig. 3a, b also shows that the percentage of LVDP recovery was significantly lower in db/db hearts that did not receive cariporide than in in db/+hearts under similar perfusion conditions. Cariporide markedly improved the recovery of LVDP in db/+ hearts, from 15–20 min to the end of reperfusion. Although to a lesser extent, a significant improvement in LVDP recovery was also observed in hearts from diabetic db/db mice. We next examined whether the difference in functional recovery between cariporide-treated and untreated hearts would also be present at a more physiological calcium concentration. A group of hearts from both db/+ and db/db mice was perfused with buffer containing 1.75 mmol/l ionised Ca2+. Under these conditions, ventricular function recovery was higher than in the presence of 0.9 mmol/l ionised Ca2+. However, cariporide again significantly increased the recovery of LVDP in both diabetic and non-diabetic hearts, as shown in Fig. 3 at 40 min of reperfusion.
Fig. 2

Left ventricular end diastolic pressure (LVEDP) during ischaemia and reperfusion in isovolumic perfused hearts from non-diabetic db/+ (solid circles) and diabetic db/db male mice (solid boxes), and in hearts from db/+ (open circles) and db/db mice (open boxes) receiving cariporide. Means±SEM, n=5 hearts in each group. *p<0.05 for difference from db/db hearts without cariporide

Fig. 3

Left ventricular developed pressure during reperfusion following no-flow ischaemia. a Hearts from non-diabetic db/+ mice receiving (open columns) or not receiving (filled columns) cariporide. b Hearts from diabetic db/db mice receiving (open columns) or not receiving (filled columns) cariporide. The horizontal bars indicate the time-period of occurrence of ventricular arrhythmias for the groups of hearts receiving (empty bars) or not receiving (filled bars) cariporide. Means±SEM, n=5 hearts in each group. The columns right of the dotted line (a, b) show recovery of developed pressure for db/+ and db/db hearts that received perfusate containing 1.75 mmol/l ionised Ca2+(401.75) *p<0.05 for difference from hearts without cariporide. §p<0.05 for difference from db/+hearts with cariporide

Reperfusion-induced arrhythmias

Reperfusion-induced arrhythmias (Fig. 4) occurred in all groups of hearts and all of them terminated spontaneously. The time-periods of occurrence of ventricular arrhythmias (from the earliest onset of arrhythmia to the latest end of arrhythmia in each group) were 15–1,635 s in db/db vs 20–1,121 s in db/+ hearts without cariporide, whereas they were 30–1,116 s in db/db and 30–882 s in db/+ hearts, respectively, in the presence of cariporide (Fig. 3). Although the incidence of VT (Fig. 5a) was 100% in both db/db and db/+ hearts, duration of VT in db/db hearts was significantly greater than in db/+ hearts. Cariporide similarly decreased the incidence of VT (to 75%) in both db/db and db/+ hearts. Duration of VT was also significantly reduced in db/db hearts in the presence of cariporide, but the short duration of VT in db/+ hearts remained unchanged.
Fig. 4

Representative recordings of reperfusion-induced ventricular arrhythmias obtained from hearts of db/db mice. a Normal sinus rhythm; b non-sustained VT; c sustained VT; d degeneration of VT into VF; e VF

Fig. 5

Incidence (%) and duration in seconds (s) of VT (a) and of VF (b) in hearts from diabetic db/db and from non-diabetic db/+ mice receiving or not receiving cariporide. Means±SEM, n=5 hearts in each group. #p<0.05 vs db/+ hearts; *p<0.05 vs without cariporide. s, seconds; %, percentage of incidence

In all db/db hearts, degeneration of VT into VF (Fig. 5b) was observed (100% incidence). This did not occur in db/+ hearts. No occurrence of VF was observed in any of the two groups of hearts receiving cariporide.

Changes in \(Na^{ + }_{i} \)in hearts from db/db mice

There were no differences in the mean values of \(Na^{ + }_{i} \)obtained from the 23Na NMR spectra during control perfusion between db/db (13.9±1.5 mmol/l, n=8) and db/+ hearts (14.2±0.7 mmol/l, n=8). These values were unchanged in hearts receiving cariporide (15.2±1.9 and 15.1±0.9 mmol/l for the db/db and db/+ hearts, respectively, n=5 hearts in each group). As shown in Fig. 6, \(Na^{ + }_{i} \) increased more rapidly during no-flow ischaemia in hearts from diabetic db/db mice than in hearts from non-diabetic db/+mice, reaching 179.0±4.9% and 158.0±8.1% of control values at end ischaemia, respectively (p<0.05). Hearts receiving cariporide showed a similar time course of \(Na^{ + }_{i} \) increase to that observed in the absence of cariporide over the first 20 min of ischaemia. Although not significantly different, a tendency towards a lesser increase in \(Na^{ + }_{i} \) was observed in the group of db/+hearts receiving cariporide. However, in both db/db and db/+ hearts, the presence of cariporide significantly reduced the rise in Na+i\(Na^{ + }_{i} \) at the end of ischaemia (157.6±9.4% vs 179.0±4.9% in db/db hearts and 126.2±10.9 vs 158.0±8.1% in db/+ hearts).
Fig. 6

Changes (mean percent of control values±SEM) in \(Na^{ + }_{i} \) during 30 min of no-flow ischaemia in hearts from non-diabetic db/+(filled circles) and from diabetic db/db mice (filled boxes) that did not receive cariporide, and in hearts from db/+ (open circles) and db/db (open boxes) mice that received cariporide. n=8 hearts per group without cariporide and n=5 hearts per group with cariporide. *p<0.05 vs without cariporide. Inset:23Na NMR spectra of isolated perfused mouse heart showing \(Na^{ + }_{i} \) increase during ischaemia. Nae is the extracellular peak shifted by TmDOTP5−

Changes in pHi in hearts from db/db mice

Since the presence of the NHE inhibitor cariporide reduced the rise in \(Na^{ + }_{i} \) at the end of ischaemia and since NHE contributes significantly to the integrated control of pHi during ischaemia and reperfusion [15], we examined pHi during ischaemia and reperfusion. As shown in Fig. 7, the two main observations from this pHi investigation were: (1) cariporide significantly accentuated the decrease in pHi during ischaemia in diabetic hearts but not in non-diabetic hearts; and (2) the rate of pHi recovery was markedly increased over the first 25 min of reperfusion, particularly at the very beginning of reperfusion, in diabetic compared with non-diabetic hearts.
Fig. 7

Mean values±SEM of pHi during 30 min of no-flow ischaemia and reperfusion in a hearts from non-diabetic db/+ (solid circles) and from diabetic db/db mice (solid boxes) that did not receive cariporide, in b hearts from diabetic db/db mice that received cariporide (open boxes), and c in hearts from non-diabetic db/+ mice that received cariporide (open circles). *p<0.05 vs db/+ (a); *p<0.05 vs db/db without cariporide (b). n=7 db/db with or without cariporide, n=6 db/+ with or without cariporide


The main feature of this study was that increased susceptibility to ischaemia–reperfusion in db/db hearts mainly consisted of a higher duration of VT and the degeneration of VT into VF upon reperfusion after global ischaemia. This was associated with delayed and lower levels of recovery of developed pressure. It could be argued that the relatively low level of ionised Ca2+ used in the present work may have affected the functional response of the hearts to ischaemia and reperfusion injury, as well as the response to cariporide treatment. LVDP recovery was indeed higher in hearts perfused with a more physiological Ca2+ concentration, i.e. 1.75 mmol/l vs 0.9 mmol/l. However, the comparison of LVDP recovery after 40 min of reperfusion in the presence and absence of cariporide in each of the two groups of mouse hearts clearly showed a beneficial effect of cariporide (30.0±3.4% of the pre-ischaemic level vs 12.1±4.3% in the absence of cariporide for the db/db, p=0.012, and 44.6±4.3 vs 31.6±1.8%, p=0.023, for the db/+ hearts). In the only previous report on ischaemic sensitivity in hearts from db/db mice, perfused working hearts demonstrated decreased post-ischaemic recovery of coronary flow compared with control hearts, and because coronary flow is an important determinant of cardiac function the decreased post-ischaemic function could also reflect impaired flow as a result of vascular or endothelial dysfunction in addition to myocyte dysfunction. No such difference was observed in the present work, since coronary flow recovery after 5 min of reperfusion averaged 71% (1.57±0.15 ml/min, n=11) and 73.8% (1.77±0.26 ml/min, n=12) in db/+ and db/db hearts, respectively. In the above mentioned study, treatment aimed at normalising metabolic disturbances (with an activator of peroxisome proliferator-activated receptor-α) failed to improve mechanical recovery after ischaemia–reperfusion, even though carbohydrate oxidation was stimulated and palmitate oxidation was decreased. This finding suggested that in the severe type 2 diabetic db/db mice, at least not all the adverse effects of diabetes on the recovery of contractile function after ischaemia–reperfusion were due to altered metabolism [6].

An important determinant of sensitivity to ischaemia–reperfusion is altered ion homeostasis, especially disturbances in \(Na^{ + }_{i} \) handling [11, 12]. This study is the first to demonstrate that myocardial \(Na^{ + }_{i} \) increased substantially in isolated mouse hearts during ischaemia and increased significantly more in hearts from diabetic db/db hearts than in hearts from control db/+ mice. In this context, the present pHi data are of particular interest. Indeed, Fig. 7a shows a trend towards a lesser pHi decrease during the last 10 min of ischaemia in db/db hearts, although the differences observed between pHi values of these hearts and those of db/+ mice over the same period were not significant. The accentuated pHi decrease in cariporide-treated db/db hearts over this same period of ischaemia (Fig. 7b) seems to indicate that NHE was not totally inhibited in diabetic hearts. No information is available to date concerning NHE activity in type 2 diabetic db/db mouse hearts. In streptozotocin-induced diabetic rats, we previously reported a ~50% increase in levels of \(Na^{ + }_{i} \) at baseline [27], these results being consistent with a decrease in NHE activity in this model [28]. No such increase was found here in db/db hearts. We can therefore infer from these data and from the pHi data that NHE activity would at least not be decreased in type 2 diabetic db/db mouse hearts. Consistent with the pHi data in db/db hearts, this study also shows that the NHE inhibitor cariporide significantly reduced the rise in \(Na^{ + }_{i} \) at end ischaemia. However, and surprisingly, this effect appeared less pronounced in diabetic (−21%) than in control (−31%) hearts. This apparent contradistinction could be explained if Na+ influx during ischaemia also occurs via other routes than NHE, which may be Na+/HCO3 cotransport [29] and the voltage-gated Na+ channel, especially a slowly inactivating component of Na+ current (INaL) [17, 21, 30, 31]. We have previously shown that such a current is partially inhibited by known NHE blockers and also reduced in diabetic rat hearts [30]. Since the db/db hearts show an increased \(Na^{ + }_{i} \) accumulation, this must therefore result from NHE- and/or Na+/HCO3 cotransport-mediated Na+ influx. More Na+ influx means more acid-equivalent efflux. Because pHi at the end of ischaemia shows no significant difference between db/db and db/+ hearts, we can envisage two possibilities: (1) there is a higher ischaemic proton production in the db/db hearts; and/or (2) the intracellular H+ buffering capacity is decreased. The cariporide-sensitive Na+ influx during ischaemia in control hearts may have resulted not only from inhibition of NHE, but also from some degree of cariporide-induced inhibition of INaL, the latter being reduced in diabetic hearts. Nevertheless, cariporide treatment was associated with a similar lower incidence of VT in both groups of hearts but with a markedly shorter duration of VT in diabetic db/db hearts. Moreover, the most prominent effect of cariporide was that it totally inhibited the degeneration of VT into VF in db/db hearts, the incidence of which was 100% without cariporide, whereas none of the db/+ hearts exhibited VF. In this regard, \(Na^{ + }_{i} \) accumulation has been shown by others to be a strong predictor of VF [32]. Of particular interest is our observation of a high incidence of VF in diabetic db/db hearts with exacerbated ischaemia–induced \(Na^{ + }_{i} \) increase. It is known that increases in \(Na^{ + }_{i} \) in ischaemic cardiomyocytes generate Ca2+ loading via reverse Na+/Ca2+ exchange, which mediates much of the damage incurred upon reperfusion [33, 34]. Since diabetic db/db mouse hearts have a deficiency in cardiomyocyte Ca2+ handling, in particular an increased Ca2+ leakage from the sarcoplasmic reticulum, as recently shown by Belke et al. [35], this may in turn precipitate the occurrence of ventricular arrhythmias [36]. Our data indicate that reducing accumulation of \(Na^{ + }_{i} \) to a modest extent may indeed have marked beneficial effects on the occurrence of VF and on ventricular function.

It has also previously been shown that one factor promoting degeneration of VT into VF during early reperfusion is the rate at which extracellular pH is restored [23] and extracellular pH restoration influences pHi [37]. We report here a markedly higher recovery rate of pHi in db/db hearts during reperfusion, with an abrupt slope over the first 5 min, compared with db/+ hearts. However, since this pHi recovery rate on reperfusion was not influenced by cariporide in either db/+ or db/db hearts, this seems to exclude the possibility of pHi recovery rate playing a significant role in the development of VF, which was highly cariporide-sensitive in db/db hearts. Therefore, the rapid rise of pHi on reperfusion, which has been shown to be mediated principally by metabolite washout (lactate and CO2) over the first 2–3 min and also by Na+/HCO3 cotransport [38, 39, 40], may suggest changes in the activity of these mechanisms in db/db hearts.


In this study we found that hearts from db/db mice had enhanced susceptibility to cardiac ischaemia, associated with a higher rise in \(Na^{ + }_{i} .\) The data also suggest a higher sensitivity of db/db hearts to the protective effect of cariporide, as assessed particularly by the marked inhibition of the degeneration of VT into VF upon reperfusion. It must be acknowledged that data obtained with the use of a leptin-signalling-deficient model to represent type 2 diabetes should be interpreted with caution. In view of emerging evidence for cardiac effects of leptin and that leptin may represent an autocrine/paracrine regulator of cardiac function [41], future work will have to examine the possible interplay between leptin-signalling pathway(s) and \(Na^{ + }_{i} \)-regulating mechanisms, especially NHE.



This study was supported by a grant from Fondation de France and by an Action Concertée Incitative ‘Plateformes d’explorations fonctionnelles thématisées 2003’.


  1. 1.
    Devereux RB, Roman MJ, Paranicas M et al (2000) Impact of diabetes on cardiac structure and function. The Strong Heart Study. Circulation 101:2271–2276Google Scholar
  2. 2.
    Shehadeh A, Regan TJ (1995) Cardiac consequences of diabetes mellitus. Clin Cardiol 18:301–305PubMedGoogle Scholar
  3. 3.
    Frustaci A, Kajstura J, Chimenti C et al (2000) Myocardial cell death in human diabetes. Circ Res 87:1123–1132PubMedGoogle Scholar
  4. 4.
    Maddaford TG, Russell JC, Pierce GN (1997) Postischemic cardiac performance in the insulin-resistant JCR:LA-cp rat. Am J Physiol Heart Circ Physiol 42:H1187–H1192Google Scholar
  5. 5.
    Belke DD, Larsen TJ, Gibbs EM, Severson DL (2000) Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrin Metab 279:E1104–E1113Google Scholar
  6. 6.
    Aasum E, Hafstad AD, Severson DL, Larsen TS (2003) Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 52:434–441PubMedCrossRefGoogle Scholar
  7. 7.
    Leibel RL, Chung WK, Chua SR Jr (1997) The molecular genetics of rodent single gene obesities. J Biol Chem 272:31937–31940CrossRefPubMedGoogle Scholar
  8. 8.
    Wyse BM, Dulin WE (1970) The influence of age and dietary conditions on diabetes in the db mouse. Diabetologia 6:268–273CrossRefPubMedGoogle Scholar
  9. 9.
    Cavaghan MK, Ehrmann DA, Polonsky KS (2000) Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 106:329–333PubMedCrossRefGoogle Scholar
  10. 10.
    Semeniuk LM, Kryski AJ, Severson DL (2002) Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol 283:H976–H982PubMedGoogle Scholar
  11. 11.
    El Banani H, Bernard M, Baetz D et al (2000) Changes in intracellular sodium and pH during ischaemia–reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia. Cardiovasc Res 47:688–696CrossRefPubMedGoogle Scholar
  12. 12.
    Imahashi K, Kusuoka H, Hashimoto K, Yoshioka J, Yamaguchi H, Nishimura T (1999) Intracellular sodium accumulation during ischemia as the substrate for reperfusion injury. Circ Res 84:1401–1406PubMedGoogle Scholar
  13. 13.
    Pogwizd SM, Sipido KR, Verdonck F, Bers DM (2003) Intracellular Na in animal models of hypertrophy and heart failure: contractile function and arrhythmogenesis. Cardiovasc Res 57:887–896CrossRefPubMedGoogle Scholar
  14. 14.
    Khandoudi N, Bernard M, Cozzone P, Feuvray D (1990) Intracellular pH and role of Na+/H+ exchange during ischaemia and reperfusion of normal and diabetic rat hearts. Cardiovasc Res 24:873–878PubMedCrossRefGoogle Scholar
  15. 15.
    Feuvray D (1997) The regulation of intracellular pH in the diabetic myocardium. Cardiovasc Res 34:48–54CrossRefPubMedGoogle Scholar
  16. 16.
    Hartmann M, Decking UKM (1999) Blocking Na+–H+ exchange by cariporide reduces Na+ overload in ischemia and is cardioprotective. J Mol Cell Cardiol 31:1985–1995CrossRefPubMedGoogle Scholar
  17. 17.
    Baetz D, Bernard M, Pinet C et al (2003) Different pathways for sodium entry in cardiac cells during ischemia and early reperfusion. Mol Cell Biochem 242:115–120CrossRefPubMedGoogle Scholar
  18. 18.
    Anzawa R, Bernard M, Baetz D, Confort-Gouny S, Gascard JP, Feuvray D (2003) Increased susceptibility to ischaemia–reperfusion of hearts from diabetic (db/db) mice: a functional and 23Na NMR spectroscopy study. Eur J Heart Fail 2:17 (Abstract)Google Scholar
  19. 19.
    Pijnappel WWF, Van den Boogart, De Beer R, Van Ormondt D (1992) SVD-based quantification of magnetic resonance signals. J Magn Reson 97:122–134Google Scholar
  20. 20.
    Vanhamme L, Van den Boogart A, Van Huffel S (1997) Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 129:35–43CrossRefPubMedGoogle Scholar
  21. 21.
    Van Emous JG, Nederhoff MGJ, Ruigrok TJC, Van Echteld CJA (1997) The role of the Na+ channel in the accumulation of intracellular Na+ during myocardial ischemia: consequences for post-ischemic recovery. J Mol Cell Cardiol 29:85–96CrossRefPubMedGoogle Scholar
  22. 22.
    Scholz W, Albus U, Counillon L et al (1995) Protective effect of HOE 642, a selective sodium–hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion. Cardiovasc Res 29:260–268CrossRefPubMedGoogle Scholar
  23. 23.
    Avkiran M, Ibuki C (1992) Reperfusion-induced arrhythmias. A role for washout of extracellular protons? Circ Res 71:1429–1440PubMedGoogle Scholar
  24. 24.
    Walker MJA, Curtis MJ, Hearse DJ et al (1988) The Lambeth Conventions: guidelines for the study of arrhythmias in ischemia, infarction, and reperfusion. Cardiovasc Res 22:447–455PubMedGoogle Scholar
  25. 25.
    Brooks WW, Conrad CH (1999) Differences between mouse and rat myocardial contractile responsiveness to calcium. Comp Biochem Physiol A Mol Integr Physiol 124:139–147CrossRefPubMedGoogle Scholar
  26. 26.
    Headrick JP, Peart J, Hack B, Garnham B, Matherne GP (2001) 5′-adenosine monophosphate and adenosine metabolism, and adenosine responses in mouse, rat and guinea-pig heart. Comp Biochem Physiol A Mol Integr Physiol 130:615–631CrossRefPubMedGoogle Scholar
  27. 27.
    Lagadic-Gossmann D, Feuvray D (1991) Intracellular sodium activity in papillary muscle from diabetic rat hearts. Exp Physiol 76:147–149PubMedGoogle Scholar
  28. 28.
    Le Prigent K, Lagadic-Gossmann D, Feuvray D (1997) Modulation by pHo and intracellular Ca2+ of Na+–H+ exchange in diabetic rat isolated ventricular myocytes. Circ Res 80:253–260PubMedGoogle Scholar
  29. 29.
    Ten Hove M, Nederhoff MG, Van Echteld CJ (2005) Relative contributions of Na+/H+ exchange and Na+/HCO3 cotransport to ischemic \({\left( {Na^{ + }_{i} } \right)}\) overload in isolated rat hearts. Am J Physiol Heart Circ Physiol 288:H287–H292CrossRefPubMedGoogle Scholar
  30. 30.
    Chattou S, Coulombe A, Diacono J, Le Grand B, John G, Feuvray D (2000) Slowly inactivating component of sodium current in ventricular myocytes is decreased by diabetes and partially inhibited by known Na+–H+ exchange blockers. J Mol Cell Cardiol 32:1181–1192CrossRefPubMedGoogle Scholar
  31. 31.
    Pinet C, Le Grand B, John GW, Coulombe A (2002) Thrombin facilitation of voltage-gated sodium channel activation in human cardiomyocytes. Implications for ischemic sodium loading. Circulation 106:2098–2103CrossRefPubMedGoogle Scholar
  32. 32.
    Neubauer S, Newell JB, Ingwall JS (1992) Metabolic consequences and predictability of ventricular fibrillation in hypoxia. A 31P- and 23Na-nuclear magnetic resonance study of the isolated rat heart. Circulation 86:302–310PubMedGoogle Scholar
  33. 33.
    Tani M, Neely JR (1989) Role of intracellular Na+ in Ca2+ overload and depressed recovery of ventricular function of reperfused ischemic rat hearts. Circ Res 65:1045–1056PubMedGoogle Scholar
  34. 34.
    Pogwizd SM, Schlotthauer K, Li L, Yuan W, Bers DM (2001) Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium–calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res 88:1159–1167PubMedCrossRefGoogle Scholar
  35. 35.
    Belke DD, Swanson EA, Dillmann WH (2004) Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 53:3201–3208PubMedCrossRefGoogle Scholar
  36. 36.
    Wehrens XHT, Lehnart SE, Huang F et al (2003) FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 113:829–840CrossRefPubMedGoogle Scholar
  37. 37.
    Vaughan-Jones RD, Wu M-L (1990) Extracellular H+ inactivation of Na+–H+ exchange in the sheep cardiac Purkinje fibre. J Physiol (Lond) 428:441–466Google Scholar
  38. 38.
    Vandenberg JI, Metcalfe JC, Grace AA (1993) Mechanisms of pHi recovery after global ischemia in the perfused heart. Circ Res 72:993–1003PubMedGoogle Scholar
  39. 39.
    Khandoudi N, Bernard M, Cozzone PJ, Feuvray D (1995) Mechanisms of intracellular pH regulation during postischemic reperfusion of diabetic rat hearts. Diabetes 44:196–202PubMedCrossRefGoogle Scholar
  40. 40.
    Baetz D, Haworth RS, Avkiran M, Feuvray D (2002) The ERK pathway regulates Na+–HCO3 cotransport activity in adult rat cardiomyocytes. Am J Physiol Heart Circ Physiol 283:H2102–H2109PubMedGoogle Scholar
  41. 41.
    Purdham DM, Zou MX, Rajapurohitam V, Karmazyn M (2004) Rat heart is a site of leptin production and action. Am J Physiol Heart Circ Physiol 287:H2877–H2884CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • R. Anzawa
    • 1
  • M. Bernard
    • 2
  • S. Tamareille
    • 1
  • D. Baetz
    • 1
  • S. Confort-Gouny
    • 2
  • J. P. Gascard
    • 1
  • P. Cozzone
    • 2
  • D. Feuvray
    • 1
  1. 1.UMR CNRS 8078Université Paris-Sud XI, Hôpital Marie LannelongueLe Plessis RobinsonFrance
  2. 2.CNRS UMR 6612-CRMBMFaculté de MédecineMarseilleFrance
  3. 3.Division of Cardiology, Department of Internal MedicineJikei University School of MedicineTokyoJapan

Personalised recommendations